ABT-737-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEABT-737Cat. No.: HY-50907CAS No.: 852808-04-9分式: CHClNOS分量: 813.43作靶點: Bcl-2 Family; Autophagy; Mitophagy作通路: Apoptosis; Autophagy儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 50 mg/mL (6

2、1.47 mM; Need ultrasonic)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (3.07 mM); Suspended solution; Need ultrasonic2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (3.07 mM); Suspended solution; Need ultrasonic3. 請依序添加每種溶劑： 10% DMSO 90% corn oil1/3 Master of Sm

3、all Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (3.07 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 ABT-737種類似 BH3 的 Bcl-xL，Bcl-2 和 Bcl-w 的抑制劑，EC50 值分別為 78.7 nM，30.3 nM 和 197.8nM。IC50 & Target Bcl-2 Bcl-xL Bcl-W Bcl-B30.3 nM (EC50) 78.7 nM (EC50) 197.8 nM (EC50) 1820 nM (EC50)Autophagy Mitophagy體

4、外研究 ABT-737 and ATO inhibits proliferation and induces apoptosis in SGC-7901 and MGC-803 cells inconcentration- and time-dependent manner, and shows a synergistic effect. ABT-737 disturbs the binding ofB cell lymphoma (Bcl)-2 homologous antagonist killer and Bcl-extra large 1. ABT-737 induces a BAX/

5、BAK-dependent impairment of maximal O2 consumption rate in sensitive cells. Stable BCL-2 overexpression inMCF10A cells induces an ABT-737-sensitive primed for death state. ABT-737 induces dose-dependentimpairment of maximal O2 consumption rate in B-cell lymphoma cells 2. ABT-737 induces apoptosis an

6、dsynergizes with chemotherapy,and disrups BCL-2/BAX heterodimerization and induces BAX conformationalchange in AML cells 3.體內(nèi)研究 ABT-737 (50 mg/kg, i.p.) and ATO significantly suppress SGC-7901 xenograft growth, synergistically inhibittumour growth and induce apoptosis in vivo 1. ABT-737 suppresses t

7、he leukemia burden by 48% and 53%at the 20 and 30 mg/kg dose levels, respectively 3.PROTOCOLKinase Assay 3 To determine the binding affinity of GST-BCL-2 family proteins to the FITC-conjugated BH3 domain of BIM(FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR), FPAs are performed as follows. Briefly, 100 nM of GS

8、T-BCL-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM ofFITC-BIM BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarizationis measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black pl

9、ate.IC50s are determined using GraphPad Prism software.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 2 Cells are treated with ABT-737, ABT-263, or vehicle (DMSO) for 4 h in XF24 assay medium (6104 MCF10Acells, see medium composition below)

10、or RPMI 1640 medium (1106 B-cell lymphoma cells) and apoptosis isanalyzed by Annexin-V-binding/PI exclusion or by sub-diploid nuclei determination. FACS analysis isperformed on Becton Dickinson FACScan or FACScalibur instruments. Data analysis is performed withCellQuest software.MCE has not independ

11、ently confirmed the accuracy of these methods. They are for reference only.Animal For intraperitoneal (i.p.) administration, 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEAdministration 3 30% propylene glycol, 5% Tween 80, 65% D5W (

12、5% dextrose in water) (pH 45; final concentration ofDMSO 1%). Mice injected with FD/Raf-1:ER cells are treated with either ABT-737 (20 and 30mg/kg/mouse every day i.p. for 21 days starting on day 1 post-cell injection (n=9-10 mice per group) orvehicle or left untreated (control); mice injected with

13、human KG-1 cells are treated with 30 mg/kg ABT-737starting on day 18 post-cell injection. For noninvasive imaging of FD/Raf-1:ER-luc cells, anesthetized miceare injected with 150 mg/kg of D-luciferin and placed for imaging in the In Vivo Imaging System with totalimaging time of 2 min.MCE has not ind

14、ependently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Haematologica. 2017 Apr;102(4):755-764. Cancer Lett. 2019 Jul 15;461:102-111. Pharmaceutics. 2019 May 27;11(5). pii: E247. ACS Med Chem Lett. 2015 Jun 22;6(8):948-52. Eur J Pharm Sci. 2018 May 31;121:243-250.

15、See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Sun XP, et al. ABT-737 Synergizes with Arsenic Trioxide to Induce Apoptosis of Gastric Carcinoma Cells In Vitro and In Vivo.J Int MedRes. 2012;40(4):1251-64.2. Clerc P, et al. Polster BM.Rapid Detection of an ABT-737-Sensitive Primed for Death State in Cells Using Microplate-BasedRespirometry.PLoS One. 2012;7(8):e42487. Epub 2012 Aug 3.3. Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemi